Torsten Hoffmann, chief operating officer at Silence Therapeutics PLC (LON:SLN) chats to Proactive's Andrew Scott following the release of their preliminary 2017 results.
Hoffmann says the big focus for them is working towards filing their first GalNAc-siRNA CTA (clinical trial authorisation) for the treatment of liver-related iron overload disorders by the end of 2018.
Five senior managers have recently been recruited to spearhead the clinical drive.
Meet Scancell Holdings Plc, Advanced Blast & Ballistic Systems Ltd and TokenCommunities Plc at our event, London, 08 March 2018.Register here >>